Image source: © 2025 Krish Capital Pty.Ltd

Highlights

  • Canaccord lifts price target to USD 36 from USD 28; rating Hold.
  • HSBC and HSBC Global Research both downgrade earlier views to Hold in April.
  • MarketBeat data shows six analysts at Hold; consensus target around USD 36.

Smith & Nephew plc (NYSE: SNN) received a price target increase from Canaccord Genuity Group, moving to USD 36 from USD 28 while maintaining a Hold rating, according to a recent research note. The revision follows a period of reassessment across the sell-side: HSBC shifted its stance from Buy to Hold on April 25, and HSBC Global Research moved from “strong-buy” to Hold the same day. Aggregated MarketBeat data indicates six analysts currently rate the shares Hold, with a consensus price objective of approximately USD 36, implying measured upside from recent trading levels.

Operationally, Smith & Nephew develops and sells medical devices across three divisions: Orthopaedics; Sports Medicine & ENT; and Advanced Wound Management. Product lines span knee and hip implants, trauma and other reconstruction systems, arthroscopic enabling technologies, sports medicine joint repair, ENT tools, and comprehensive wound care solutions. This diversified portfolio provides exposure to elective procedure volumes, hospital capital spending, and post-acute care trends, while also introducing execution and reimbursement sensitivities across multiple markets.

From a rating perspective, the cluster of Hold recommendations suggests analysts see a balanced risk-reward profile. Potential supports include stabilization in elective procedures, mix benefits from higher-margin technologies, and ongoing productivity initiatives. Offsetting factors may include pricing pressure in commoditized implant categories, procurement dynamics with large hospital networks, and the investment needed to maintain innovation across wide product families. Currency movements and regional demand variability also remain watch points for near-term estimates.

Valuation anchored to the USD 36 consensus target implies a market that expects incremental improvement rather than rapid re-rating.